RV
RVPH.US Reviva Pharmaceuticals Holdings Inc.
- Market cap
- USD 4.65M
- P/E
- -
- P/B
- 0.35x
- ROE
- -48.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RVPH.US undervalued?
Graham numberThe Graham number of Reviva Pharmaceuticals Holdings Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Reviva Pharmaceuticals Holdings Inc. fundamental analysis
No fundamental analysis for Reviva Pharmaceuticals Holdings Inc. yet.
Reviva Pharmaceuticals Holdings Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-def…
Full company profileReviva Pharmaceuticals Holdings Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Reviva Pharmaceuticals Holdings Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | -725K | - | - | - | - | - | - |
| Operating Income | -1.12M | -377K | -2.43M | -10.1M | -24.3M | -39.5M | -30.8M | -20.2M | -3.24T |
| EBITDA | -1.10M | -376K | -2.43M | -8.52M | 3.92M | 260K | 918K | -19.8M | -6.73T |
| Net Income | -1.68M | -847K | -3.78M | -8.52M | -24.3M | -39.3M | -29.9M | -19.9M | -6.33T |
| EPS | -16 | -6.11 | -25 | -12 | -25 | -33 | -18 | -5.48 | -479,142 |
| Balance Sheet | |||||||||
| Total Assets | 65.2M | 2.60K | 8.76M | 31.4M | 18.9M | 23.7M | 15.5M | 15.9M | 18.6T |
| Total Liabilities | 6.09M | 6.81M | 3.30M | 2.72M | 10.5M | 18.0M | 14.7M | 7.28M | 5.48T |
| Shareholders' Equity | 59.2M | -6.81M | 5.47M | 28.7M | 8.39M | 5.72M | 813K | 8.65M | 13.1T |
| Cash & Short-term Investments | 65.2M | 193.00 | 8.76M | 29.7M | 18.5M | 23.4M | 13.5M | 14.4M | 17.5T |
| Total Debt | - | 3.77M | - | - | - | - | 458K | 407K | 44.4B |
| Cash Flow | |||||||||
| Operating Cash Flow | -1.07M | -218K | -4.07M | -10.7M | -19.0M | -28.3M | -33.5M | -24.6M | -2.91T |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 4.00 | 3.00 | 0.00 |
| Free Cash Flow | -1.07M | -218K | -4.07M | -10.7M | -19.0M | -28.3M | -33.5M | -24.6M | -10.8T |
| Ratios | |||||||||
| ROE | -2.8% | - | -69.2% | -29.7% | -290.0% | -686.5% | -3,682.0% | -229.7% | -48.4% |
| ROA | -2.6% | -32,570.5% | -43.2% | -27.1% | -128.6% | -165.7% | -193.0% | -124.8% | -34.1% |
| Debt to Equity | - | - | - | - | - | - | 0.56x | 0.05x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Reviva Pharmaceuticals Holdings Inc. dividends
Reviva Pharmaceuticals Holdings Inc. has not paid dividends in the last 8 fiscal years.
Last stock split: 1:20 on Mar 9, 2026.
Who owns Reviva Pharmaceuticals Holdings Inc.
- Insiders 7.72%
- Institutions 8.23%
- Public & others 84.05%
- Shares outstanding 13.1M
- Free float 11.9M
Top funds holding RVPH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Extended Equity Market Fund E | 369K | 0.14% | +569.15% | Dec 2025 |
| Extended Equity Market Fund B | 369K | 0.14% | +569.15% | Dec 2025 |
| NT Ext Eq Mkt Idx Fd DC Lending Tier 5 | 3.62K | 0.03% | +0.70% | Mar 2026 |
Top institutions holding RVPH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Highbridge Capital Management, LLC | 762K | 5.81% | 0.00% | Mar 2026 |
| Armistice Capital, LLC | 592K | 4.52% | 0.00% | Mar 2026 |
| Vanguard Capital Management, LLC | 118K | 0.90% | 0.00% | Mar 2026 |
| Geode Capital Management, LLC | 73.0K | 0.56% | -93.04% | Mar 2026 |
| Renaissance Technologies Corp | 43.0K | 0.33% | 0.00% | Mar 2026 |
| Virtu Financial LLC | 32.9K | 0.25% | 0.00% | Mar 2026 |
| Vanguard Fiduciary Trust Co | 31.6K | 0.24% | 0.00% | Mar 2026 |
| State Street Corp | 19.2K | 0.15% | -95.00% | Mar 2026 |
| BlackRock Inc | 18.6K | 0.14% | -95.00% | Mar 2026 |
| HRT FINANCIAL LLC | 18.4K | 0.14% | -40.78% | Mar 2026 |
| Northern Trust Corp | 10.5K | 0.08% | -95.00% | Mar 2026 |
| Morgan Stanley - Brokerage Accounts | 8.53K | 0.07% | -97.47% | Mar 2026 |
| EMC Capital Management(TX) | 6.70K | 0.05% | +3.88% | Jun 2026 |
| UBS Group AG | 5.27K | 0.04% | -98.53% | Mar 2026 |
| Vanguard Global Advisers, LLC | 3.12K | 0.02% | 0.00% | Mar 2026 |
| Group One Trading, LLC | 3.11K | 0.02% | -0.29% | Mar 2026 |
| Tower Research Capital LLC | 2.19K | 0.02% | 0.00% | Mar 2026 |
| Advisor Group Holdings, Inc. | 1.22K | 0.01% | 0.00% | Mar 2026 |
| Larson Financial Group, LLC | 833.00 | 0.01% | -95.00% | Mar 2026 |
| TD Waterhouse Canada Inc | 625.00 | 0.00% | -95.00% | Mar 2026 |
Reviva Pharmaceuticals Holdings Inc. company profile
- Company name
- Reviva Pharmaceuticals Holdings Inc.
- Ticker
- RVPH.US
- Exchange
- USA Stocks
- Listed since
- Oct 18, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- December
- Address
- 10080 N. Wolfe Road, Cupertino, CA, United States, 95014
- Phone
- 408 501 8881
- Website
- revivapharma.com
About Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Reviva Pharmaceuticals Holdings Inc. management
2- Dr. Laxminarayan Bhat Ph.D.Founder, CEO, President & Director · born 1966
- Mr. Narayan PrabhuCFO, Treasurer & Secretary · born 1972